Abstract
Introduction: Sufficient data pertaining to the impact of the Coronavirus disease 2019 (COVID-19) on pediatric cancer patients is still lacking. The aim of this prospective study was to describe clinical management and outcomes of COVID-19 in pediatric oncology patients.
Patients and methods: Conducted between May 1, 2020 and November 30, 2020, this study included 76 pediatric oncology patients with confirmed COVID-19. Remdesivir (RDV) was the antiviral therapy used.
Results: The median age of patients was 9 years. Sixty patients were on first line treatment. Hematological malignancies constituted 86.8% of patients. Severe to critical infections were 35.4% of patients. The commonest symptom was fever (93.4%). Chemotherapy was delayed in 59.2% of patients and doses were modified in 30.2%. The 60-day overall survival (OS) stood at 86.8%, with mortalities occurring only among critical patients. Of sixteen acute leukemia patients in the first induction therapy, 13 survived and 10 achieved complete remission. A negative RT-PCR within 2 weeks and improvement of radiological findings were statistically related to disease severity (P = .008 and .002, respectively). Better OS was associated with regression of radiological findings after 30 days from infection (P = .002). Forty-five patients received RDV, 42.1% had severe and critical forms of infection compared to 25.7% in the No-RDV group and yet OS was comparable in both groups.
Conclusion: Most pediatric cancer patients with COVID-19 should have good clinical outcomes except for patients with critical infections. Cancer patients can tolerate chemotherapy including induction phase, alongside COVID-19 treatment. In severe and critical COVID-19, RDV might have a potential benefit.
Keywords: COVID-19; SARS-CoV-2; immunocompromised patients; pediatric cancer; remdesivir.
【저자키워드】 COVID-19, SARS-CoV-2, Immunocompromised patients, remdesivir., pediatric cancer, 【초록키워드】 Treatment, coronavirus disease, antiviral therapy, Coronavirus disease 2019, therapy, Mortality, Hematological malignancies, pediatric, disease severity, Prospective Study, Infection, Immunocompromised patients, Remdesivir, Symptom, outcome, Clinical outcome, Chemotherapy, COVID-19 treatment, infections, survival, Fever, oncology, Patient, Cancer patients, Immunocompromised, Clinical management, Critical, patients, leukemia, RDV, dose, Regression, malignancy, cancer patient, Complete Remission, both groups, median age, critical patients, doses, MOST, negative RT-PCR, mortalities, oncology patients, Complete, benefit, radiological finding, form, comparable, Better, survived, statistically, in both groups, oncology patient, with COVID-19, 【제목키워드】 experience, Developing,